US3868220A - Process for extracting procainamide from blood - Google Patents
Process for extracting procainamide from blood Download PDFInfo
- Publication number
- US3868220A US3868220A US387546A US38754673A US3868220A US 3868220 A US3868220 A US 3868220A US 387546 A US387546 A US 387546A US 38754673 A US38754673 A US 38754673A US 3868220 A US3868220 A US 3868220A
- Authority
- US
- United States
- Prior art keywords
- blood
- alcoholic
- water
- accordance
- procainamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008280 blood Substances 0.000 title claims abstract description 70
- 210000004369 blood Anatomy 0.000 title claims abstract description 70
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960000244 procainamide Drugs 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 39
- 239000002904 solvent Substances 0.000 claims abstract description 40
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 38
- 239000000084 colloidal system Substances 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 66
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 25
- 239000003513 alkali Substances 0.000 claims description 18
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 150000008282 halocarbons Chemical class 0.000 claims description 8
- 229920001206 natural gum Polymers 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 8
- 239000002245 particle Substances 0.000 description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 2
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- -1 pentane and hexane) Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- WZSDWSACAGBYQU-UHFFFAOYSA-N 2-(dimethylamino)-3-phenylprop-2-enal Chemical compound CN(C)C(C=O)=CC1=CC=CC=C1 WZSDWSACAGBYQU-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GEHMBYLTCISYNY-UHFFFAOYSA-N Ammonium sulfamate Chemical compound [NH4+].NS([O-])(=O)=O GEHMBYLTCISYNY-UHFFFAOYSA-N 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 244000090599 Plantago psyllium Species 0.000 description 1
- 235000010451 Plantago psyllium Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WZRRZVUZWWMSKH-UHFFFAOYSA-N n'-naphthalen-1-ylethane-1,2-diamine;hydrochloride Chemical compound Cl.C1=CC=C2C(NCCN)=CC=CC2=C1 WZRRZVUZWWMSKH-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173845—Amine and quaternary ammonium
- Y10T436/174614—Tertiary amine
Definitions
- Procainamide is an antiarrhythmic agent, the effects of which are particularly beneficial in treating ventricular arrhythmias. Ventricular extrasystoles and ventricular tachycardia may be controlled within an hour after oral or intramuscular administration or within a few minutes after intravenous infusion of the drug. By judicious administration of procainamide, digitalis-induced ventricular extrasystoles and tachycardia may at times be controlled. Procainamide may also be of value in the control of an auricular arrhythmia.
- procainamide be administered orally.
- parenteral administration e.g., intramuscular
- suggested dosages are available to the physician, each patient must of course be treated as a separate case. It is generally felt that blood levels of procainamide ranging from about 4 parts per million (hereinafter ppm.) to about 7 ppm. are optimal.
- a bedside test for determining procainamide blood levels is particularly desirable because of the urgency of treatment for patients suffering from a cardiac arrhythmia.
- the problem to which this invention is directed is the removal of procainamide from small quantities of blood by a procedure which can be carried out in an efficient manner without the use of a centrifuge or similar separation equipment. Once the procainamide is removed from the blood, a quantitative analysis may be carried out.
- the process of this invention is a process for extracting procainamide from blood and may be used on as little as a fraction of a drop of blood.
- the process comprises basically four steps that may be summarized as follows:
- the blood residue is used here, and throughout the specification, to describe the residue remaining after the solvent containing procainamide is separated from the extraction mixture.
- the blood residue may be re-extracted one or more times with additional solvent.
- the size of the blood sample to be analyzed for procainamide is not critical, although it is important that the exact amount of the sample be known. It is an important advantage of this invention that the extraction process may be run on very small amounts of blood (as little as about /2 drop). Generally, the blood sample will be about 25 to microliters (about to 3 drops).
- the blood sample is first mixed with an alcoholic alkali.
- the amount of alcoholic alkali used is not critical, but generally the amount of alkali used will be approximately equal in volume to the blood sample.
- the purpose of the alcoholic alkali is to convert the procainamide salt (procainamide is in the blood in the form of a salt) to the free base.
- the base used should be a strong one; sodium hydroxide, potassiium hydroxide, and tetramethylammonium hydroxide are preferred, with sodium hydroxide and potassium hydroxide being particularly preferred.
- a solvent is added to the mixture.
- Any solvent may be used as long as: (i) it is water-immiscible and (ii) it will dissolve procainamide base.
- Exemplary of the solvents which may be used in the process of this invention are aliphatic hydrocarbons (e.g., pentane and hexane), halogenated hydrocarbons (e.g., chloroform and methylene chloride), petroleum ether, and aromatic hydrocarbons (e.g., benzene and toluene).
- the halogenated hydrocarbons are preferred solvents, chloroform and methylene chloride being particularly preferred.
- volume ratio of solvent to blood sample is not critical to this invention. Generally, however, a volume ratio of solvent to blood will be between about 6:1 and about 10:1. After adding the solvent to the blood sample/alcoholic alkali mixture, the entire mixture is again stirred.
- a water-soluble colloid is added to the vessel (in which the extraction is carried out) containing the blood sample, alcoholic alkali, and solvent.
- the water-soluble colloid absorbs the excess water in the blood and forms a small mass containing the blood solids. This mass will rest on the bottom of the vessel allowing the solvent layer (containing the procainamide) to be poured off.
- water-soluble colloid as used herein is a term of art.
- the materials are not watersoluble in the same way as, for example, salt or sugar, but rather they swell when they come into contact with water.
- the water-soluble colloid that may be used in the process ofthis invention may be chosen from synthetic materials or from natural gums.
- Exemplary of the synthetic materials contemplated for use in this invention are sodium carboxymethylcellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and polyvinyl alcohol.
- Exemplary of the natural gums are locust bean, guar, acacia, karaya, ghatti, agar, algin, pectin, xanthan, and psyllium seed.
- the synthetic water-soluble colloids are preferred since they are usually obtainable in purer form than the natural gums. The impurities often present in natural gums prevent them from swelling as cleanly in water as the synthetic colloids.
- additional solvent may be mixed with the blood residue, and then poured off and combined with the prior extract. This procedure may be repeated more than once.
- procainamide originally in the blood sample is extracted by the procedure of this invention into the solvent.
- the amount of procainamide in solution may be determined using methods known to those skilled in the art.
- Example 1 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumlates. 50 ul of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
- a drop of a 0.2 percent solution of potassium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod.
- 0.3 ml. of methylene chloride is added to the beaker and the mixture is stirred well.
- mg. of soidum carboxymethylcellulose Cellulose Gum 7H, a-product of Hercules, Inc.
- the carboxymethylcellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear methylene chloride is then poured off into a clean l ml. beaker.
- a second 0.3 ml. portion of methylene chloride is added to the first beaker, stirred, and the methylene chloride poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the methylene chloride.)
- Example 2 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
- a drop of a 0.2 percent solution of potassium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod.
- 0.3 ml. of chloroform is added to the beaker and the mixture is stirred well.
- 5 mg. of sodim carboxymethylcellulose Cellulose Gum 7H, a product of Hercules, Inc.
- the carboxymethylcellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear chloroform is then poured offinto a clean 1 ml. beaker.
- a second 0.3 ml. portion of chloroform is added to the first beaker, stirred, and the methylene chloride poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the chloroform.
- Example 3 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
- a drop of a 0.2 percent solution of sodium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod.
- 0.3 ml. of methylene chloride is added to the beaker and the mixture is stirred well.
- 5 mg. of sodium carboxymethylcellulose (Cellulose Gum 7H, a product of Hercules, Inc.) is added to the beaker and the mixture is again stirred. (The carboxymethylcellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear methylene chloride is then poured off into a clean 1 ml. beaker.
- Example 4 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
- a drop of a 0.2 percent solution of potassium hydroxide in methanol is added to the beaker, and the mixture is stirred with a'glass stirring rod.
- 0.3 ml. of methylene chloride is added to the beaker and the mixture is stirred well.
- 5 mg. of methyl cellulose is added to the beaker and the mixture is again stirred. (The methyl cellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear methylene chloride is then poured off into a clean 1 ml. beaker.
- a second 0.3 ml. -portion of methylene chloride is added to the first beaker, stirred, and the methylene chloride poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the methylene chloride.)
- Example 5 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
- a drop of 0.2 percent solution of sodium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod.
- 0.3 ml. of chloroform is added to the beakerand the mixture is stirred well.
- 5 mg. of pectin is added to the beaker and the mixture is again stirred. (The pectin forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear chloroform is then poured off into a clean 1 ml. beaker.
- a second 0.3 ml. portion of chloroform is added to the first beaker, stirred, and the chloroform poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the chloroform.)
- Example 6 The 1 ml. beaker of Example 1 containing the methylene chloride solution of procainamide is placed on a heating unit and evaporated to dryness.
- a drop of 0.1 N hydrochloric acid is added to the residue and the beaker is shaken to effect solution of the residue.
- a drop of 0.2 percent sodium nitrite solution is added to the beaker.
- the beaker is shaken and then allowed to stand for 1 minute.
- a drop of 10% ammonium sulfamate solution is added to the beaker.
- the beaker is shaken and then allowed to stand for 1 minute.
- N-(1-naphthyl)ethylenediamine hydrochloride is added to the beaker.
- the color of the mixture in the beaker is compared with a set of standards prepared from 50 ul. portions of procainamide solutions containing 2,4,8, and 12 parts per million of procainamide.
- Example 7 A paper disc (18 mm. diameter) is cut from filter paper (Whatman No. 120) and fitted tightly into a 22 mm. polyethylene snap cap to, act as a receptacle. 4 Drops of a 2.5 percent aqueous solution of sodium bisulfate are added to the disc, which is then allowed to dry for 24 hours.
- a drop of a 0.02 percent solution of dimethylaminocinnamaldehyde in methanol is added to a methylene chloride solution of procainamide in a 1 ml. beaker (prepared as in Example 1).
- the resultant solution is poured onto the treated paper disc in the receptacle and it is evaporated using heat provided by an electric lamp.
- a process for extracting procainamide from blood that comprises:
- water-soluble colloid is selected from the group consisting of sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, and polyvinyl alcohol.
- alcoholic alkali is selected from the group consisting of alcoholic sodium hydroxide, alcoholic potassium hydroxide, and alcoholic tetramethylammonium hydroxide.
- alcoholic alkali is selected from the group consisting of alcoholic sodium hydroxide and alcoholic potassium hydroxide.
- water-immiscible solvent is selected from the group consisting of aliphatic hydrocarbons, halogenated hydrocarbons, petroleum ether, and aromatic hydrocarbons.
- water-immiscible solvent is selected from the group consisting of chloroform and methylene chloride.
- a process in accordance with claim 1 which comprises re-extracting the blood residue with additional solvent.
- alcoholic alkali is selected from the group consisting of alcoholic sodium, alcoholic potassium and alcoholic tetramethylammonium hydroxide
- water-soluble colloid is selected from the group consisting of natural gum, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and polyvinyl alcohol
- water-immiscible solvent is selected from the group consisting of aliphatic hydrocarbons, halogenated hydrocarbons, petroleum ether and aromatic hydrocarbons.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Procainamide may be extracted from blood by a process which comprises first mixing the blood with an alcoholic base, followed by the addition of a solvent, addition of a water-soluble colloid, and separation of the solvent which contains the procainamide.
Description
United States Patent [191 Klinger [4 1 Feb. 25, 1975 PROCESS FOR EX TRACTING PROCAINAMIDE FROM BLOOD [75] Inventor: Harry Klinger, Summit, NJ.
[73] Assignee: E. R. Squibb & Sons, Inc.,
Princeton, NJ.
[22] Filed: Aug. 13, 1973 [21] Appl. No.: 387,546
[52] U.S. Cl. 23/230 B, 260/684, 260/705 [51] Int. CL. B01d 11/00, G0ln 31/02, GOln 33/16 [58] Field of Search 23/230 B; 260/112 B, 122,
[56] References Cited UNITED STATES PATENTS 3,681,283 8/1972 Yueh 210/54 X 3,706,660 12/1972 Hagan et al 210/54 X OTHER PUBLICATIONS Clinical Chemistry, Vol. 18, p. 643, Rapid Gas Chromatographic Measurement of Plasma Procainamide Concentration, Atkinson, Jr. et al.
Journal of the American Chemical Society, Vol. 66, p. 692-697, 1944, The Precipitation of Proteins by Synthetic Detergents, Putnam et al.
Primary Examiner-Morris O. Wolk Assistant Examiner-Michael S. Marcus Attorney, Agent, or FirmLawrence S. Levinson; Merle J. Smith; Donald J. Barrack [57] ABSTRACT 11 Claims, No Drawings BACKGROUND OF THE INVENTION Procainamide is an antiarrhythmic agent, the effects of which are particularly beneficial in treating ventricular arrhythmias. Ventricular extrasystoles and ventricular tachycardia may be controlled within an hour after oral or intramuscular administration or within a few minutes after intravenous infusion of the drug. By judicious administration of procainamide, digitalis-induced ventricular extrasystoles and tachycardia may at times be controlled. Procainamide may also be of value in the control of an auricular arrhythmia.
It is preferred that procainamide be administered orally. However, parenteral administration (e.g., intramuscular) may be necessary. While suggested dosages are available to the physician, each patient must of course be treated as a separate case. It is generally felt that blood levels of procainamide ranging from about 4 parts per million (hereinafter ppm.) to about 7 ppm. are optimal.
At present there are methods known for quantitatively measuring procainamide blood levels. One such method is the modified Bratton and Marshall procedure; see Journal of Pharmacology and Experimental Therapeutics 102, -15 (1951). Other methods for the quantitative determination of procainamide utilize gas chromatography (see Clinical Chemistry 18, 643 (1972)) and fluorimetry (see Journal of the American Medical Associatin 215 (9), 1454 (1971)). As now run, the above procedures require relatively large amounts of blood (i.e., about 3 to 10 milliliters) and a centrifuge for separation purposes.
It is the purpose of this invention to enable doctors (or nurses or technicians) to make a quantitative determination of procainamide in blood using a few drops (or even as little as a'fraction of a drop) of blood. A bedside test for determining procainamide blood levels is particularly desirable because of the urgency of treatment for patients suffering from a cardiac arrhythmia.
SUMMARY OF THE INVENTION The problem to which this invention is directed is the removal of procainamide from small quantities of blood by a procedure which can be carried out in an efficient manner without the use of a centrifuge or similar separation equipment. Once the procainamide is removed from the blood, a quantitative analysis may be carried out.
The process of this invention is a process for extracting procainamide from blood and may be used on as little as a fraction of a drop of blood. The process comprises basically four steps that may be summarized as follows:
i. mixing a blood sample with alcoholic alkali;
ii. adding a solvent to the mixture and stirring;
iii. adding a water-soluble colloid to the mixture and stirring; and
iv. separating the solvent from the blood residue. (The expression blood residue" is used here, and throughout the specification, to describe the residue remaining after the solvent containing procainamide is separated from the extraction mixture.) To assure that all of the procainamide has been removed from the blood sample, the blood residue may be re-extracted one or more times with additional solvent.
DETAILED DESCRIPTION OF THE INVENTION The size of the blood sample to be analyzed for procainamide is not critical, although it is important that the exact amount of the sample be known. It is an important advantage of this invention that the extraction process may be run on very small amounts of blood (as little as about /2 drop). Generally, the blood sample will be about 25 to microliters (about to 3 drops).
The blood sample is first mixed with an alcoholic alkali. The amount of alcoholic alkali used is not critical, but generally the amount of alkali used will be approximately equal in volume to the blood sample. The purpose of the alcoholic alkali is to convert the procainamide salt (procainamide is in the blood in the form of a salt) to the free base. The base used should be a strong one; sodium hydroxide, potassiium hydroxide, and tetramethylammonium hydroxide are preferred, with sodium hydroxide and potassium hydroxide being particularly preferred.
After stirring the alcoholic alkali with the blood sample, a solvent is added to the mixture. Any solvent may be used as long as: (i) it is water-immiscible and (ii) it will dissolve procainamide base. Exemplary of the solvents which may be used in the process of this invention are aliphatic hydrocarbons (e.g., pentane and hexane), halogenated hydrocarbons (e.g., chloroform and methylene chloride), petroleum ether, and aromatic hydrocarbons (e.g., benzene and toluene). The halogenated hydrocarbons are preferred solvents, chloroform and methylene chloride being particularly preferred. As will be appreciated by one skilled in the art, the volume ratio of solvent to blood sample is not critical to this invention. Generally, however, a volume ratio of solvent to blood will be between about 6:1 and about 10:1. After adding the solvent to the blood sample/alcoholic alkali mixture, the entire mixture is again stirred.
The above mixing facilitates passage of procainamide from the alkalinized blood into the solvent. However, at this stage of the extraction process the blood has a tendency to float on the solvent surface and small fibrous particles are sometimes distributed throughout the solvent layer. These problems make a clean separation of the solvent layer from the blood residue difficult.
To facilitate a clean separation of the solvent layer from the blood residue a water-soluble colloid is added to the vessel (in which the extraction is carried out) containing the blood sample, alcoholic alkali, and solvent. The water-soluble colloid absorbs the excess water in the blood and forms a small mass containing the blood solids. This mass will rest on the bottom of the vessel allowing the solvent layer (containing the procainamide) to be poured off.
The expression water-soluble colloid as used herein is a term of art. The materials are not watersoluble in the same way as, for example, salt or sugar, but rather they swell when they come into contact with water. The water-soluble colloid that may be used in the process ofthis invention may be chosen from synthetic materials or from natural gums. Exemplary of the synthetic materials contemplated for use in this invention are sodium carboxymethylcellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and polyvinyl alcohol. Exemplary of the natural gums are locust bean, guar, acacia, karaya, ghatti, agar, algin, pectin, xanthan, and psyllium seed. The synthetic water-soluble colloids are preferred since they are usually obtainable in purer form than the natural gums. The impurities often present in natural gums prevent them from swelling as cleanly in water as the synthetic colloids.
Mixing of the water-soluble colloid with the blood sample, alcoholic alkali, and solvent proceeds until the colloid has formed a mass. The solvent containing the procainamide is then poured off.
To be certain that all of the procainamide has been removed from the blood sample additional solvent may be mixed with the blood residue, and then poured off and combined with the prior extract. This procedure may be repeated more than once.
Essentially all of the procainamide originally in the blood sample is extracted by the procedure of this invention into the solvent. The amount of procainamide in solution may be determined using methods known to those skilled in the art.
The following examples are presented to further illustrate this invention.
Example 1 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumlates. 50 ul of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
A drop of a 0.2 percent solution of potassium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod. 0.3 ml. of methylene chloride is added to the beaker and the mixture is stirred well. mg. of soidum carboxymethylcellulose (Cellulose Gum 7H, a-product of Hercules, Inc.) is added to the breaker and the mixture is again stirred. (The carboxymethylcellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear methylene chloride is then poured off into a clean l ml. beaker.
A second 0.3 ml. portion of methylene chloride is added to the first beaker, stirred, and the methylene chloride poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the methylene chloride.)
Example 2 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
A drop of a 0.2 percent solution of potassium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod. 0.3 ml. of chloroform is added to the beaker and the mixture is stirred well. 5 mg. of sodim carboxymethylcellulose (Cellulose Gum 7H, a product of Hercules, Inc.) is added to the beaker and the mixture is again stirred. (The carboxymethylcellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear chloroform is then poured offinto a clean 1 ml. beaker.
A second 0.3 ml. portion of chloroform is added to the first beaker, stirred, and the methylene chloride poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the chloroform.
Example 3 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
A drop of a 0.2 percent solution of sodium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod. 0.3 ml. of methylene chloride is added to the beaker and the mixture is stirred well. 5 mg. of sodium carboxymethylcellulose (Cellulose Gum 7H, a product of Hercules, Inc.) is added to the beaker and the mixture is again stirred. (The carboxymethylcellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear methylene chloride is then poured off into a clean 1 ml. beaker.
' A second 0.3 ml. portion of methylene chloride is added to the first beaker, stirred, and the methylene chloride poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the methylene chloride.)
Example 4 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
A drop of a 0.2 percent solution of potassium hydroxide in methanol is added to the beaker, and the mixture is stirred with a'glass stirring rod. 0.3 ml. of methylene chloride is added to the beaker and the mixture is stirred well. 5 mg. of methyl cellulose is added to the beaker and the mixture is again stirred. (The methyl cellulose forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear methylene chloride is then poured off into a clean 1 ml. beaker.
A second 0.3 ml. -portion of methylene chloride is added to the first beaker, stirred, and the methylene chloride poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the methylene chloride.)
Example 5 Using a blood lancet, the fingertip skin is pierced and the finger is squeezed until a drop of blood accumulates. 50 ul. of blood is drawn from the drop into a disposable pipet and is blown into a 1 ml. beaker.
A drop of 0.2 percent solution of sodium hydroxide in methanol is added to the beaker, and the mixture is stirred with a glass stirring rod. 0.3 ml. of chloroform is added to the beakerand the mixture is stirred well. 5 mg. of pectin is added to the beaker and the mixture is again stirred. (The pectin forms a gelatinous blob). Stirring is continued until no floating particles are observed, and the clear chloroform is then poured off into a clean 1 ml. beaker.
A second 0.3 ml. portion of chloroform is added to the first beaker, stirred, and the chloroform poured off into the second beaker to mix with the first portion. (At this stage, essentially all of the procainamide from the 50 ul. of blood is dissolved in the chloroform.)
The following examples illustrate how the procainamide extracted from a drop of blood can be quantitatively measured.
Example 6 The 1 ml. beaker of Example 1 containing the methylene chloride solution of procainamide is placed on a heating unit and evaporated to dryness.
A drop of 0.1 N hydrochloric acid is added to the residue and the beaker is shaken to effect solution of the residue.
A drop of 0.2 percent sodium nitrite solution is added to the beaker. The beaker is shaken and then allowed to stand for 1 minute.
A drop of 10% ammonium sulfamate solution is added to the beaker. The beaker is shaken and then allowed to stand for 1 minute.
A drop of N-(1-naphthyl)ethylenediamine hydrochloride is added to the beaker.
After several minutes, the color of the mixture in the beaker is compared with a set of standards prepared from 50 ul. portions of procainamide solutions containing 2,4,8, and 12 parts per million of procainamide.
Example 7 A paper disc (18 mm. diameter) is cut from filter paper (Whatman No. 120) and fitted tightly into a 22 mm. polyethylene snap cap to, act as a receptacle. 4 Drops of a 2.5 percent aqueous solution of sodium bisulfate are added to the disc, which is then allowed to dry for 24 hours.
A drop of a 0.02 percent solution of dimethylaminocinnamaldehyde in methanol is added to a methylene chloride solution of procainamide in a 1 ml. beaker (prepared as in Example 1). The resultant solution is poured onto the treated paper disc in the receptacle and it is evaporated using heat provided by an electric lamp.
When the disc is completely dry, its color is compared with a set of standards prepared from 50 ul. portions of procainamide solutions containing 2,4,8, and 12. part per million of procainamide and treated as above.
I claim:
1. A process for extracting procainamide from blood that comprises:
(i) mixing a blood sample with alcoholic alkali;
(ii) adding to the mixture of (i) a water-immiscible solvent which will dissolve the procainamide in the blood;
(iii) adding a water-soluble colloid to the mixture of blood sample, alcoholic alkali, and waterimmiscible solvent; and
(iv) separating the solvent from the blood residue.
2. A process in accordance with claim 1 wherein the water-soluble colloid is a natural gum.
3. A process in accordance with claim 1 wherein the water-soluble colloid is selected from the group consisting of sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, and polyvinyl alcohol.
4. A process in accordance with claim 3 wherein the water-soluble colloid is sodium carboxymethylcellulose.
5. A process in accordance with claim I wherein the alcoholic alkali is selected from the group consisting of alcoholic sodium hydroxide, alcoholic potassium hydroxide, and alcoholic tetramethylammonium hydroxide.
6. A process in accordance with claim 5 wherein the alcoholic alkali is selected from the group consisting of alcoholic sodium hydroxide and alcoholic potassium hydroxide.
7. A process in accordance with claim 1 wherein the water-immiscible solvent is selected from the group consisting of aliphatic hydrocarbons, halogenated hydrocarbons, petroleum ether, and aromatic hydrocarbons.
8. A process in accordance with claim 7 wherein the water-immiscible solvent is a halogenated hydrocarbon.
9. A process in accordance with claim 8 wherein the water-immiscible solvent is selected from the group consisting of chloroform and methylene chloride.
10. A process in accordance with claim 1 which comprises re-extracting the blood residue with additional solvent.
1 l. A process in accordance with claim 1 wherein the alcoholic alkali is selected from the group consisting of alcoholic sodium, alcoholic potassium and alcoholic tetramethylammonium hydroxide; the water-soluble colloid is selected from the group consisting of natural gum, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and polyvinyl alcohol; and the water-immiscible solvent is selected from the group consisting of aliphatic hydrocarbons, halogenated hydrocarbons, petroleum ether and aromatic hydrocarbons.
UNITED STATES PATENT OFFICE I 1 CERTIFICATE OF CORRECTION PATENT NO. 3,868,220 DATED February 25, 1975 INVENTOR(S) Harry Klingel It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
On abstract page, inventor's name should read--Klingel-.
Column 1, line 31, "Associatin" should rsad-Association-a Column 2, line 18, "potassiium" should readpotassium-.
Column 3, line 28, "accumlates" should read-accumulates.
Column 4, line 2, insert parentheses after the word "form."- to read--form.)-.
Column 6, line 41, "alcoholic sodium" should read-alcoholic sodium hydroxide--; "alcoholic potassium" should read alcoholic potassium hydroxide-.
Signed and sealed this 27th day of May 1975.
(SEAL) Attest:
c. MARSHALL DANN Commissioner of Patents and Trademarks RUTH C. MASON Attesting Officer
Claims (11)
1. A PROCESS FOR EXTRACTING PROCAINAMIDE FROM BLOOD THAT COMPRISES: (I) MIXING A BLOOD SAMPLE WITH ALCOHOLIC ALKALI; (II) ADDING TO THE MIXTURE OF (I) A WATER-IMMISCIBLE SOLVENT WHICH WILL DISSOLVE THE PROCAINAMIDE IN THE BLOOD; (III) ADDING A WATER-SOLUBLE COLLOID TO THE MIXTURE OF BLOOD SAMPLE, ALCOHOLIC ALKALI, AND WATER-IMMISCIBLE SOLVENT; AND (IV) SEPARATING THE SOLVENT FROM THE BLOOD RESIDUE.
2. A process in accordance with claim 1 wherein the water-soluble colloid is a natural gum.
3. A process in accordance with claim 1 wherein the water-soluble colloid is selected from the group consisting of sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, and polyvinyl alcohol.
4. A process in accordance with claim 3 wherein the water-soluble colloid is sodium carboxymethylcellulose.
5. A process in accordance with claim 1 wherein the alcoholic alkali is selected from the group consisting of alcoholic sodium hydroxide, alcoholic potassium hydroxide, and alcoholic tetramethylammonium hydroxide.
6. A process in accordance with claim 5 wherein the alcoholic alkali is selected from the group consisting of alcoholic sodium hydroxide and alcoholic potassium hydroxide.
7. A process in accordance with claim 1 wherein the water-immiscible solvent is selected from the group consisting of aliphatic hydrocarbons, halogenated hydrocarbons, petroleum ether, and aromatic hydrocarbons.
8. A process in accordance with claim 7 wherein the water-immiscible solvent is a halogenated hydrocarbon.
9. A process in accordance with claim 8 wherein the water-immiscible solvent is selected from the group consisting of chloroform and methylene chloride.
10. A process in accordance with claim 1 which comprises re-extracting the blood residue with additional solvent.
11. A process in accordance with claim 1 wherein the alcoholic alkali is selected from the group consisting of alcoholic sodium, alcoholic potassium and alcoholic tetramethylammonium hydroxide; the water-soluble colloid is selected from the group consisting of natural gum, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose and polyvinyl alcohol; and the water-immiscible solvent is selected from the group consisting of aliphatic hydrocarbons, halogenated hydrocarbons, petroleum ether and aromatic hydrocarbons.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US387546A US3868220A (en) | 1973-08-13 | 1973-08-13 | Process for extracting procainamide from blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US387546A US3868220A (en) | 1973-08-13 | 1973-08-13 | Process for extracting procainamide from blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3868220A true US3868220A (en) | 1975-02-25 |
Family
ID=23530340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US387546A Expired - Lifetime US3868220A (en) | 1973-08-13 | 1973-08-13 | Process for extracting procainamide from blood |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3868220A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681283A (en) * | 1970-09-02 | 1972-08-01 | Gen Mills Inc | Waste treatment with nucleoprotein flocculating agent |
| US3706660A (en) * | 1971-03-25 | 1972-12-19 | Squibb & Sons Inc | Process for removal of particle-forming proteins from blood sera |
-
1973
- 1973-08-13 US US387546A patent/US3868220A/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681283A (en) * | 1970-09-02 | 1972-08-01 | Gen Mills Inc | Waste treatment with nucleoprotein flocculating agent |
| US3706660A (en) * | 1971-03-25 | 1972-12-19 | Squibb & Sons Inc | Process for removal of particle-forming proteins from blood sera |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Johnson et al. | Gas-chromatographic determination of theophylline in human serum and saliva | |
| SILBER et al. | An improved procedure for the determination of hydrocortisone in human plasma | |
| Dudley | The Purification of Insulin and some of its Properties | |
| Hess et al. | The isolation of chondroitin sulfuric acid from dentin | |
| Woods et al. | Estimation of morphine in biological materials | |
| US3868220A (en) | Process for extracting procainamide from blood | |
| Levvy | The estimation of barbiturates in blood | |
| Taylor et al. | Isolation and properties of a macromolecular component of normal chick embryo tissue | |
| Andrews et al. | Cholesterosis bulbi. Case report with modern chemical identification of the ubiquitous crystals | |
| Kaul et al. | Chlorpromazine metabolism II: Determination of nonconjugated metabolites in blood of schizophrenic patients | |
| US3275416A (en) | Process and device for separating barbituric acid derivatives from biological samples, and for analyzing same | |
| Berry | The cathode-ray polarographic determination of diazepam, 7-chloro-1, 3-dihydro-1-methyl-5-phenyl-2H-1, 4-benzodiazepine-2-one, in human plasma | |
| Oi et al. | Changes in plasma glucose, insulin, glucagon, catecholamine, and glycogen contents in tissues during development of alloxan diabetes mellitus in rats | |
| US3839317A (en) | Digoxin complexes | |
| JPS63203682A (en) | Novel flavonoid and glycoside thereof | |
| US2862851A (en) | Aldosterone, process for preparation and compositions thereof | |
| Searcy et al. | Micro measurement of serum total lipids | |
| Persson | Studies on the accumulation of certain barbiturates in the brain of the human foetus | |
| Kahn | The Kahn precipitation test for syphilis | |
| Helbacka et al. | Studies on Blood and Meat Spots in the Hen’s Egg: 2. Some Chemical and Histological Characteristics of Blood and Meat Spots | |
| Wadsworth et al. | Further studies of the chemical reactions underlying the coagulation of the blood. The activity of lecithin | |
| Hobsley et al. | An extraction technique for the estimation of Evans blue in plasma | |
| WICK et al. | A METHOD FOR MEASURING AND THE EFFECT OF ADRENOCORTICOTROPIC HORMONE ON LIPIDSOLUBLE REDUCING SUBSTANCES OF RABBIT PLASMA | |
| Dwivedi et al. | Quantitative estimation of Holarrhena antidysenterica bark total alkaloids in crude drugs and in the body fluids of man and rat | |
| Irwin et al. | Biochemical Analysis of Human Salivary Mucin: I. The Possibility of Cholesterol in Mucin |